Cargando…

Randomized phase II study of weekly carfilzomib 70 mg/m(2) and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients

In this randomized phase II study (GEM-KyCyDex, clinicaltrials gov. Identifier: NCT03336073), the combination of weekly carfilzomib 70 mg/m(2), cyclophosphamide and dexamethasone (KCd) was compared to carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM) after 1-3 prior l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puertas, Borja, González-Calle, Verónica, Sureda, Anna, Moreno, María José, Oriol, Albert, González, Esther, Rosiñol, Laura, López, Jordi, Escalante, Fernando, Martínez-Lopez, Joaquín, Carrillo, Estrella, Clavero, Esther, Ríos-Tamayo, Rafael, Rey-Bua, Beatriz, González-Rodríguez, Ana Pilar, Dourdil, Victoria, de Arriba, Felipe, González, Sonia, Pérez-de-Oteyza, Jaime, Hernández, Miguel T., García-Mateo, Aránzazu, Bargay, Joan, Bladé, Joan, Lahuerta, Juan José, San Miguel, Jesús F., Ocio, Enrique M., Mateos, María-Victoria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2023
Materias:	Article - Plasma Cell Disorders
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542845/ https://www.ncbi.nlm.nih.gov/pubmed/37102598 http://dx.doi.org/10.3324/haematol.2022.282490

Ejemplares similares

Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
por: Rodríguez-Otero, Paula, et al.
Publicado: (2019)

Severity of Covid-19 Clinical Outcomes and Mortality in Multiple Myeloma Patients over Year 1 of the Pandemic
por: Martínez-López, Joaquín, et al.
Publicado: (2021)

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis
por: Capra, Marcelo, et al.
Publicado: (2021)

A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
por: Encinas, Cristina, et al.
Publicado: (2022)

P878: SELINEXOR IN COMBINATION WITH DARATUMUMAB-BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF RELAPSE OR REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS OF THE PHASE 2, MULTICENTER GEM-SELIBORDARA STUDY
por: Gonzalez-Calle, Veronica, et al.
Publicado: (2023)

Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma
por: Puig, Noemí, et al.
Publicado: (2022)

High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to low-dose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex
por: Zhou, Xiang, et al.
Publicado: (2023)

Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) Database
por: McCurdy, Arleigh, et al.
Publicado: (2022)

Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel
por: Leleu, Xavier, et al.
Publicado: (2022)

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
por: Moreau, Philippe, et al.
Publicado: (2023)

Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
por: Botta, Cirino, et al.
Publicado: (2023)

Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial
por: Puig, Noemí, et al.
Publicado: (2020)

Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations()
por: Lopez, Aurelio, et al.
Publicado: (2015)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
por: Rosiñol, Laura, et al.
Publicado: (2023)

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
por: Medina, Alejandro, et al.
Publicado: (2020)

Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group
por: Mosquera Orgueira, Adrian, et al.
Publicado: (2022)

Expression of p53 protein isoforms predicts survival in patients with multiple myeloma
por: Rojas, Elizabeta A., et al.
Publicado: (2022)

Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients
por: Medina, Alejandro, et al.
Publicado: (2020)

Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials
por: Lopez-Anglada, Lucia, et al.
Publicado: (2018)

Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial
por: Puig, Noemi, et al.
Publicado: (2021)

Anti-BCMA CAR T-cell Therapy: Changing the Natural History of Multiple Myeloma
por: Puertas, Borja, et al.
Publicado: (2022)

Defining a set of standardised outcome measures for newly diagnosed patients with multiple myeloma using the Delphi consensus method: the IMPORTA project
por: Blade, Joan, et al.
Publicado: (2018)

Carfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement
por: Español, Ignacio, et al.
Publicado: (2017)

Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma
por: Puig, Noemí, et al.
Publicado: (2021)

Plasmas en todas partes /
por: Bravo, Silvia
Publicado: (1991)

Plasmas en todas partes /
por: Bravo, Silvia
Publicado: (2001)

A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility
por: Misiewicz-Krzeminska, Irena, et al.
Publicado: (2018)

Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study
por: Usmani, Saad Z., et al.
Publicado: (2023)

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis
por: Facon, Thierry, et al.
Publicado: (2022)

An objective assessment in newly diagnosed multiple myeloma to avoid treatment complications and strengthen therapy adherence
por: Holler, Maximilian, et al.
Publicado: (2022)

Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis
por: Cuenca, Isabel, et al.
Publicado: (2020)

Matching‐adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible
por: Sonneveld, Pieter, et al.
Publicado: (2020)

NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial
por: Rosa-Rosa, Juan Manuel, et al.
Publicado: (2022)

Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution
por: Jiménez-Segura, Raquel, et al.
Publicado: (2022)

Multiple myeloma with t(11;14): impact of novel agents on outcome
por: Puertas, Borja, et al.
Publicado: (2023)

Regulation of miRNA expression by α4β1 integrin‐dependent multiple myeloma cell adhesion
por: Rodríguez‐García, Yaiza, et al.
Publicado: (2023)

Treatment of Patients with Monoclonal Gammopathy of Clinical Significance
por: Moreno, David F., et al.
Publicado: (2021)

Multiple primary cutaneous plasmacytoma a decade after a nasal solitary extramedullary plasmacytoma: a puzzling case
por: González‐Calle, Verónica, et al.
Publicado: (2016)

Drug-induced Thrombotic Microangiopathy During Maintenance Treatment in a Patient With Multiple Myeloma
por: Higuero Saavedra, Víctor, et al.
Publicado: (2019)

Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
por: Dimopoulos, M A, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_pl04hhfdnq9dlv1891mlemfrv4